Yedan Liu

Yedan Liu

Auto-generated profile, based on publicly available information

Yedan Liu

Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, Mississippi

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2022 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Closed access
PDF file
SWShaoxun Wang
Shaoxun Wang
FJFeng Jiao
Feng Jiao
JBJane J. Border
Jane J. Border
XFXing Fang
Xing Fang
RCReece F. Crumpler
Reece F. Crumpler
FFFan Fan
Fan Fan
This study demonstrates that luseogliflozin, a sodium-glucose cotransporter-2 inhibitor, improved CBF autoregulation in association with reduced vascular oxidative stress and AGEs production in the cerebrovasculature of 18-mo-old DM rats. SGLT2i also prevented BBB leakage, impaired functional hyperemia, neurodegeneration, and cognitive impairment seen in DM rats. Luseogliflozin did not have direct constrictive effects on VSMCs and MCAs isolated from normal rats. These results provide evidence that normalization of hyperglycemia with an SGLT2i can reverse cerebrovascular dysfunction and cognitive impairments in rats with long-standing hyperglycemia, possibly by ameliorating oxidative stress-caused vascular damage.

10 August 2021 in Clinical Science
Verified
Journal Article
Open access
PDF file
EGEzekiel Gonzalez-Fernandez
Ezekiel Gonzalez-Fernandez
YLYedan Liu
Yedan Liu
AAAlexander P. Auchus
Alexander P. Auchus
FFFan Fan
Fan Fan
RRRichard Roman
Richard Roman
The accumulation of extracellular amyloid-β (Aβ) and intracellular hyperphosphorylated τ proteins in the brain are the hallmarks of Alzheimer’s disease (AD). Much of the research into the pathogenesis of AD has focused on the amyloid or τ hypothesis. These hypotheses propose that Aβ or τ aggregation is the inciting event in AD that leads to downstream neurodegeneration, inflammation, brain atrophy and cognitive impairment. Multiple drugs have been developed and are effective in preventing the accumulation and/or clearing of Aβ or τ proteins. However, clinical trials examining these therapeutic agents have failed to show efficacy in preventing or slowing the progression of the disease. Thus, there is a need for fresh perspectives and the evaluation of alternative therapeutic targets in this field. Epidemiology studies have revealed significant overlap between cardiovascular and cerebrovascular risk factors such as hypertension, diabetes, atherosclerosis and stroke to the development of cognitive impairment. This strong correlation has given birth to a renewed focus on vascular contributions to AD and related dementias. However, few genes and mechanisms have been identified. 20-Hydroxyeicosatetraenoic acid (20-HETE) is a potent vasoconstrictor that plays a complex role in hypertension, autoregulation of cerebral blood flow and blood–brain barrier (BBB) integrity. Multiple human genome-wide association studies have linked mutations in the cytochrome P450 (CYP) 4A (CYP4A) genes that produce 20-HETE to hypertension and stroke. Most recently, genetic variants in the enzymes that produce 20-HETE have also been linked to AD in human population studies. This review examines the emerging role of 20-HETE in AD and related dementias.

1 June 2021 in Prostaglandins & Other Lipid Mediators
Verified
Journal Article
Closed access
YLYedan Liu
Yedan Liu
HZHuawei Zhang
Huawei Zhang
CWCeleste Yc. Wu
Celeste Yc. Wu
TYTina Yu
Tina Yu
XFXing Fang
Xing Fang
FFFan Fan
Fan Fan

1 February 2022 in Physiological Genomics
Verified
Journal Article
Closed access
PDF file
EGEzekiel Gonzalez-Fernandez
Ezekiel Gonzalez-Fernandez
LFLetao Fan
Letao Fan
SWShaoxun Wang
Shaoxun Wang
YLYedan Liu
Yedan Liu
WGWenjun Gao
Wenjun Gao
RRRichard Roman
Richard Roman
Hypertension is a leading risk factor for stroke, heart disease, chronic kidney disease, vascular cognitive impairment, and Alzheimer’s disease. Previous genetic studies have nominated hundreds of genes linked to hypertension, and renal and cognitive diseases. Some have been advanced as candidate genes by showing that they can alter blood pressure or renal and cerebral vascular function in knockout animals; however, final validation of the causal variants and underlying mechanisms has remained elusive. This review chronicles 40 years of work, from the initial identification of adducin (ADD) as an ACTIN-binding protein suggested to increase blood pressure in Milan hypertensive rats, to the discovery of a mutation in ADD1 as a candidate gene for hypertension in rats that were subsequently linked to hypertension in man. More recently, a recessive K572Q mutation in ADD3 was identified in Fawn-Hooded Hypertensive (FHH) and Milan Normotensive (MNS) rats that develop renal disease, which is absent in resistant strains. ADD3 dimerizes with ADD1 to form functional ADD protein. The mutation in ADD3 disrupts a critical ACTIN-binding site necessary for its interactions with actin and spectrin to regulate the cytoskeleton. Studies using Add3 KO and transgenic strains, as well as a genetic complementation study in FHH and MNS rats, confirmed that the K572Q mutation in ADD3 plays a causal role in altering the myogenic response and autoregulation of renal and cerebral blood flow, resulting in increased susceptibility to hypertension-induced renal disease and cerebral vascular and cognitive dysfunction.

28 September 2018 in International Journal of Developmental Neuroscience
Verified
Journal Article
Closed access
YGYa Guo
Ya Guo
YZYu Zhang
Yu Zhang
Fei LiFei Li
Fei Li
PLPeipei Liu
Peipei Liu
YLYedan Liu
Yedan Liu
ZCZongbo Chen
Zongbo Chen

19 March 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
CLChen-Wei Li
Chen-Wei Li
BLBaolin Liu
Baolin Liu
BKBoxi Kang
Boxi Kang
ZLZedao Liu
Zedao Liu
YLYedan Liu
Yedan Liu
ZZZemin Zhang
Zemin Zhang
A Correction to this paper has been published: https://doi.org/10.1038/s41467-021-22248-3